Live Breaking News & Updates on Licensed Adalimumab

Celltrion Healthcare receives EU CHMP positive opinion for biosimilar adalimumab, CT-P17
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of CT-P17 (adalimumab biosimilar) for the treatment of multiple chronic inflammatory diseases
The positive opinion is based on Phase I/III study data investigating the equivalence of CT-P17 to reference adalimumab in terms of efficacy, pharmacokinetics (PK) and overall safety
If approved, CT-P17 would be the first adalimumab biosimilar with high concentration (100mg/mL) and citrate-free formulation
Celltrion Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorisation of an adalimumab biosimilar candidate referencing Humira ....

Zuzanna Grzeskiewicz , Kostenloser Wertpapierhandel , Sophia Eminson , L Adalimumab Biosimilar , Abbvie Biotechnology Ltd , European Union , European Medicines Agency , European Commission , National Library Of Medicine , Committee For Medicinal Products Human Use , Marketing Division At Celltrion Healthcare , Medicinal Products , Human Use , Houng Kim , Marketing Division , Edward Keystone , Senior Consultant Rheumatologist , Mount Sinai Hospital , European Economic Area , Celltrion Healthcare , Proposed High Concentration , Adalimumab Biosimilar , Approved Adalimumab , Licensed Adalimumab , Single Dose Study , Poster Presented ,